ECEESPE2025 ePoster Presentations Diabetes and Insulin (245 abstracts)
Quality of life in patients with diabetes mellitus
Zvezdana Jemuovic 1 , Sandra Pekic Djurdjevic 1 , Mirjana Doknic 1 , Dragana Miljic 1 , Marko Stojanovic 1 , Ivana Cekic 1 , Ivan Jevtic 1 , Boris Kurcubic 1 , Jelena Bajic 1 & Marina Nikolic Djurovic 1
1Clinic for Endocrinology, diabetes and diseases of metabolism, University Clinical Center of Serbia, Belgrade, Serbia
JOINT3523
Introduction: The prevalence of diabetes mellitus (DM) is reaching epidemic proportions in many parts of the world. People with DM have a worse quality of life (QoL) than those without chronic disease. DM is associated with a high risk of serious complications that affect the QoL.
Aim: To determine whether there is a difference in the quality of life in patients with DM2 receiving SGLT-2 inhibitor therapy compared to ones receiving insulin analogues.
Methods: Cross-sectional, case control study with 30 DM2 patients (mean age 59.7± 2.9) and 15 healthy controls, matched for age, sex and educational level, were included. DM2 patients were divided into 2 groups, 15 patients receiving SGLT2-inhibitors and 15 patients receiving insulin analogues. Measurement of glucose, HbA1c, urea, and creatinine was done. Evaluation of QoL was evaluated by QoL questionnaire - SF36. Fisher’s ANOVA analysis was used to compare means between (sub)groups.
Results: Both DM2 groups had higher levels of glucose (SGLT2inh vs insulin) vs control group (7.37±0.87 vs 8.21±1.42 vs 5.15±0.6 mmol/l, P = 0.000) as well as HbA1c (6.86±0.31 vs 7.32±0.62 vs 5.23±0.29%, P = 0.000). Patients in both SGLT2inh and insulin groups vs control group reported worse quality of life in all scales measured by SF36. Physical health – Dimension A (48.91±5.49 vs 35.73±7.16 vs 53.28±5.29 P = 0.000) and mental health – Dimension B (39.77±8.15 vs 25.06±10.11 vs 47.28±6.30, P = 0.000).
Conclusion: Use of SGLT-2 inhibitors represents a significant step forward in the treatment of patients with DM2. These drugs not only improve the control of blood glucose levels, but also significantly contribute to improving the quality of life of patients, reducing complications and facilitating daily life. Assessment of the quality of life should become part of the routine control of patients with DM2, to determine the priority for each patient at the beginning of treatment and accordingly adjust therapeutic modalities in accordance with the latest medical recommendations.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more